Inhibition of retinal and choroidal neovascularization by a novel KDR kinase inhibitor

Fumi Kinose, Giuseppe Roscilli, Stefania Lamartina, Kenneth D. Anderson, Fabio Bonelli, Stanley G. Spence, Gennaro Ciliberto, Thomas F. Vogt, Daniel J. Holder, Carlo Toniatti, Catherine J. Thut

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Purpose: Inhibition of vascular endothelial growth factor (VEGF) signaling has shown great promise for the treatment of ocular neovascular disease. Current anti-VEGF therapies in late-stage development, while efficacious, require dosing by frequent intravitreal injections that are inconvenient to patients. VEGF signaling inhibitors that demonstrate more convenient dosing regimens could lead to the improved treatment of neovascular diseases such as wet age related macular degeneration (AMD) and proliferative diabetic retinopathy (PDR). Here we describe the assessment of a KDR (VEGFR2) kinase inhibitor in two well-established models of ocular neovascularization following oral administration. Methods: A novel KDR kinase inhibitor was dosed by oral gavage for 12 days at 0, 10, 30, or 100 mg/kg in an adult male Brown Norway rat laser induced choroidal neovascularization (CNV) model. The areas of CNV lesions were quantitated by fluorescence image analysis of FITC-dextran perfused animals. The kinase inhibitor was also assessed in a rat oxygen induced retinopathy (OIR) model in which neonatal rats were placed in an oxygen chamber that delivered alternating 24 h cycles of 50% and 10% oxygen for 14 days. After 14 days of oxygen treatment, the animals were returned to room air and dosed orally for 7 days with 0, 10, or 30 mg/kg kinase inhibitor. The extent of retinal neovascularization was assessed by counting pre-retinal neovascular nuclei on histological sections. Results: At doses of 100 mg/kg, the KDR kinase inhibitor resulted in a 98% reduction in lesion size in the rat CNV model. 30 mg/kg doses of the inhibitor showed a 70% and 80% reduction in lesion size in the laser CNV and OIR models, respectively. Conclusions: Oral dosing of the described KDR kinase inhibitor effectively inhibits neovascularization in two well-established animal models of ocular neovascularization. These data suggest that compounds of this class may prove to be useful for the treatment of a variety of ocular neovascular diseases using a convenient oral dosing regimen.

Original languageEnglish
Pages (from-to)366-373
Number of pages8
JournalMolecular Vision
Volume11
Publication statusPublished - May 27 2005

Fingerprint

Retinal Neovascularization
Choroidal Neovascularization
Phosphotransferases
Oxygen
Vascular Endothelial Growth Factor A
Eye Diseases
Lasers
Therapeutics
Intravitreal Injections
Macular Degeneration
Diabetic Retinopathy
Oral Administration
Animal Models
Fluorescence
Air

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Kinose, F., Roscilli, G., Lamartina, S., Anderson, K. D., Bonelli, F., Spence, S. G., ... Thut, C. J. (2005). Inhibition of retinal and choroidal neovascularization by a novel KDR kinase inhibitor. Molecular Vision, 11, 366-373.

Inhibition of retinal and choroidal neovascularization by a novel KDR kinase inhibitor. / Kinose, Fumi; Roscilli, Giuseppe; Lamartina, Stefania; Anderson, Kenneth D.; Bonelli, Fabio; Spence, Stanley G.; Ciliberto, Gennaro; Vogt, Thomas F.; Holder, Daniel J.; Toniatti, Carlo; Thut, Catherine J.

In: Molecular Vision, Vol. 11, 27.05.2005, p. 366-373.

Research output: Contribution to journalArticle

Kinose, F, Roscilli, G, Lamartina, S, Anderson, KD, Bonelli, F, Spence, SG, Ciliberto, G, Vogt, TF, Holder, DJ, Toniatti, C & Thut, CJ 2005, 'Inhibition of retinal and choroidal neovascularization by a novel KDR kinase inhibitor', Molecular Vision, vol. 11, pp. 366-373.
Kinose F, Roscilli G, Lamartina S, Anderson KD, Bonelli F, Spence SG et al. Inhibition of retinal and choroidal neovascularization by a novel KDR kinase inhibitor. Molecular Vision. 2005 May 27;11:366-373.
Kinose, Fumi ; Roscilli, Giuseppe ; Lamartina, Stefania ; Anderson, Kenneth D. ; Bonelli, Fabio ; Spence, Stanley G. ; Ciliberto, Gennaro ; Vogt, Thomas F. ; Holder, Daniel J. ; Toniatti, Carlo ; Thut, Catherine J. / Inhibition of retinal and choroidal neovascularization by a novel KDR kinase inhibitor. In: Molecular Vision. 2005 ; Vol. 11. pp. 366-373.
@article{6acc073839454ab7aa94b7357e9ab25b,
title = "Inhibition of retinal and choroidal neovascularization by a novel KDR kinase inhibitor",
abstract = "Purpose: Inhibition of vascular endothelial growth factor (VEGF) signaling has shown great promise for the treatment of ocular neovascular disease. Current anti-VEGF therapies in late-stage development, while efficacious, require dosing by frequent intravitreal injections that are inconvenient to patients. VEGF signaling inhibitors that demonstrate more convenient dosing regimens could lead to the improved treatment of neovascular diseases such as wet age related macular degeneration (AMD) and proliferative diabetic retinopathy (PDR). Here we describe the assessment of a KDR (VEGFR2) kinase inhibitor in two well-established models of ocular neovascularization following oral administration. Methods: A novel KDR kinase inhibitor was dosed by oral gavage for 12 days at 0, 10, 30, or 100 mg/kg in an adult male Brown Norway rat laser induced choroidal neovascularization (CNV) model. The areas of CNV lesions were quantitated by fluorescence image analysis of FITC-dextran perfused animals. The kinase inhibitor was also assessed in a rat oxygen induced retinopathy (OIR) model in which neonatal rats were placed in an oxygen chamber that delivered alternating 24 h cycles of 50{\%} and 10{\%} oxygen for 14 days. After 14 days of oxygen treatment, the animals were returned to room air and dosed orally for 7 days with 0, 10, or 30 mg/kg kinase inhibitor. The extent of retinal neovascularization was assessed by counting pre-retinal neovascular nuclei on histological sections. Results: At doses of 100 mg/kg, the KDR kinase inhibitor resulted in a 98{\%} reduction in lesion size in the rat CNV model. 30 mg/kg doses of the inhibitor showed a 70{\%} and 80{\%} reduction in lesion size in the laser CNV and OIR models, respectively. Conclusions: Oral dosing of the described KDR kinase inhibitor effectively inhibits neovascularization in two well-established animal models of ocular neovascularization. These data suggest that compounds of this class may prove to be useful for the treatment of a variety of ocular neovascular diseases using a convenient oral dosing regimen.",
author = "Fumi Kinose and Giuseppe Roscilli and Stefania Lamartina and Anderson, {Kenneth D.} and Fabio Bonelli and Spence, {Stanley G.} and Gennaro Ciliberto and Vogt, {Thomas F.} and Holder, {Daniel J.} and Carlo Toniatti and Thut, {Catherine J.}",
year = "2005",
month = "5",
day = "27",
language = "English",
volume = "11",
pages = "366--373",
journal = "Molecular Vision",
issn = "1090-0535",

}

TY - JOUR

T1 - Inhibition of retinal and choroidal neovascularization by a novel KDR kinase inhibitor

AU - Kinose, Fumi

AU - Roscilli, Giuseppe

AU - Lamartina, Stefania

AU - Anderson, Kenneth D.

AU - Bonelli, Fabio

AU - Spence, Stanley G.

AU - Ciliberto, Gennaro

AU - Vogt, Thomas F.

AU - Holder, Daniel J.

AU - Toniatti, Carlo

AU - Thut, Catherine J.

PY - 2005/5/27

Y1 - 2005/5/27

N2 - Purpose: Inhibition of vascular endothelial growth factor (VEGF) signaling has shown great promise for the treatment of ocular neovascular disease. Current anti-VEGF therapies in late-stage development, while efficacious, require dosing by frequent intravitreal injections that are inconvenient to patients. VEGF signaling inhibitors that demonstrate more convenient dosing regimens could lead to the improved treatment of neovascular diseases such as wet age related macular degeneration (AMD) and proliferative diabetic retinopathy (PDR). Here we describe the assessment of a KDR (VEGFR2) kinase inhibitor in two well-established models of ocular neovascularization following oral administration. Methods: A novel KDR kinase inhibitor was dosed by oral gavage for 12 days at 0, 10, 30, or 100 mg/kg in an adult male Brown Norway rat laser induced choroidal neovascularization (CNV) model. The areas of CNV lesions were quantitated by fluorescence image analysis of FITC-dextran perfused animals. The kinase inhibitor was also assessed in a rat oxygen induced retinopathy (OIR) model in which neonatal rats were placed in an oxygen chamber that delivered alternating 24 h cycles of 50% and 10% oxygen for 14 days. After 14 days of oxygen treatment, the animals were returned to room air and dosed orally for 7 days with 0, 10, or 30 mg/kg kinase inhibitor. The extent of retinal neovascularization was assessed by counting pre-retinal neovascular nuclei on histological sections. Results: At doses of 100 mg/kg, the KDR kinase inhibitor resulted in a 98% reduction in lesion size in the rat CNV model. 30 mg/kg doses of the inhibitor showed a 70% and 80% reduction in lesion size in the laser CNV and OIR models, respectively. Conclusions: Oral dosing of the described KDR kinase inhibitor effectively inhibits neovascularization in two well-established animal models of ocular neovascularization. These data suggest that compounds of this class may prove to be useful for the treatment of a variety of ocular neovascular diseases using a convenient oral dosing regimen.

AB - Purpose: Inhibition of vascular endothelial growth factor (VEGF) signaling has shown great promise for the treatment of ocular neovascular disease. Current anti-VEGF therapies in late-stage development, while efficacious, require dosing by frequent intravitreal injections that are inconvenient to patients. VEGF signaling inhibitors that demonstrate more convenient dosing regimens could lead to the improved treatment of neovascular diseases such as wet age related macular degeneration (AMD) and proliferative diabetic retinopathy (PDR). Here we describe the assessment of a KDR (VEGFR2) kinase inhibitor in two well-established models of ocular neovascularization following oral administration. Methods: A novel KDR kinase inhibitor was dosed by oral gavage for 12 days at 0, 10, 30, or 100 mg/kg in an adult male Brown Norway rat laser induced choroidal neovascularization (CNV) model. The areas of CNV lesions were quantitated by fluorescence image analysis of FITC-dextran perfused animals. The kinase inhibitor was also assessed in a rat oxygen induced retinopathy (OIR) model in which neonatal rats were placed in an oxygen chamber that delivered alternating 24 h cycles of 50% and 10% oxygen for 14 days. After 14 days of oxygen treatment, the animals were returned to room air and dosed orally for 7 days with 0, 10, or 30 mg/kg kinase inhibitor. The extent of retinal neovascularization was assessed by counting pre-retinal neovascular nuclei on histological sections. Results: At doses of 100 mg/kg, the KDR kinase inhibitor resulted in a 98% reduction in lesion size in the rat CNV model. 30 mg/kg doses of the inhibitor showed a 70% and 80% reduction in lesion size in the laser CNV and OIR models, respectively. Conclusions: Oral dosing of the described KDR kinase inhibitor effectively inhibits neovascularization in two well-established animal models of ocular neovascularization. These data suggest that compounds of this class may prove to be useful for the treatment of a variety of ocular neovascular diseases using a convenient oral dosing regimen.

UR - http://www.scopus.com/inward/record.url?scp=25444508308&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=25444508308&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 366

EP - 373

JO - Molecular Vision

JF - Molecular Vision

SN - 1090-0535

ER -